Key result
Noninvasive diagnostic testing, including ECG, echocardiography, cardiac magnetic resonance imaging, and genetic testing, is crucial for identifying patients with hypertrophic cardiomyopathy at high risk for sudden cardiac death.
Why the study?
Does noninvasive diagnostic testing improve risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy?
Does noninvasive diagnostic testing improve risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy?
Noninvasive diagnostic modalities like ECG, CMR, and genetic testing play a crucial role in risk stratifying patients with hypertrophic cardiomyopathy for sudden cardiac death.
Supports multimodal noninvasive testing for HCM SCD risk stratification; leaves open prospective validation before guideline integration.
Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young, particularly among athletes. Identifying high risk individuals is very important for SCD prevention. The purpose of this review is to stress that noninvasive diagnostic testing is important for risk assessment. Extreme left ventricular hypertrophy and documented ventricular tachycardia and fibrillation increase the risk of SCD. Fragmented QRS and T wave inversion in multiple leads are more common in high risk patients. Cardiac magnetic resonance imaging provides complete visualization of the left ventricular chamber, allowing precise localization of the distribution of hypertrophy and measurement of wall thickness and cardiac mass. Moreover, with late gadolinium enhancement, patchy myocardial fibrosis within the area of hypertrophy can be detected, which is also helpful in risk stratification. Genetic testing is encouraged in all cases, especially in those with a family history of HCM and SCD.
No takes yet. Share an insight, caveat, or question.
Li Zhang (2014) conducted a review in Hypertrophic cardiomyopathy. Noninvasive diagnostic testing (ECG, Echocardiography, CMRI, Genetic testing) was evaluated. Noninvasive diagnostic testing, including ECG, echocardiography, cardiac magnetic resonance imaging, and genetic testing, is crucial for identifying patients with hypertrophic cardiomyopathy at high risk for sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: